Glioblastoma is the most lethal form of brain cancer in adults. Due to the ineffectiveness of current treatments, Dr. Peiwen Chen’s goal is to figure out how immune cells might be more effectively employed in targeting and eliminating brain cancer cells. Specifically, Dr. Chen aims to identify which genetic events in the cancer cells drive immune responses in glioblastoma, and to determine which immune cells are affected in this process. By characterizing the mechanisms that underlie this communication between cancer cells and immune cells in the tumor environment as well as the roles that individual genes play in this behavior, Dr. Chen hopes to uncover insights that can be used to develop novel immunotherapy strategies against this feedback loop and improve outcomes for these patients with glioblastoma.
The University of Texas MD Anderson Cancer Center | Brain Cancer | 2018 | Ronald A. DePinho, M.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Immunotherapy took center stage and dominated the headlines at AACR18.
Day 4 at AACR18 was a special day for CRI’s Dr. Antoni Ribas, and highlighted his and others’ efforts to overcome resistance to PD-1 therapy as well as insights into the role of dendritic cells.